Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 1.00 |
| ▸ | CNR2 | P34972 | 4/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | GLP1R | P43220 | 1/20 | 0.48 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | ADGRF1 | Q5T601 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339080 | 0.89 | CNR1 (0.80) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL4714656 | 0.83 | CNR1 (0.71) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5463337 | 0.82 | CNR1 (1.00) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5343828 | 0.81 | CNR1 (0.82) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5339344 | 0.79 | CNR1 (0.78) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL1316265 | 0.79 | CNR1 (1.00) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5348509 | 0.78 | CNR1 (1.00) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5336377 | 0.78 | CNR1 (0.64) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5350892 | 0.78 | CNR1 (0.64) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5335401 | 0.78 | CNR1 (0.64) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7145012-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2006-12-05 | — | — | US | claimed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | claimed |
| US-8138174-B2 | Such as N-{1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-methylidene)-4-chloro-benzenesulfonamide; pain. psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity; neurodegenerative disorders | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-03-20 | — | — | US | disclosed |
| US-8138174-B2 | Such as N-{1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-methylidene)-4-chloro-benzenesulfonamide; pain. psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity; neurodegenerative disorders | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-03-20 | — | — | US | disclosed |
| US-8063062-B2 | Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction; -chloro-N-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazolyl]-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptylamino]methylene}benzene-sulfonamide | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-11-22 | — | — | US | disclosed |
| US-8063062-B2 | Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction; -chloro-N-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazolyl]-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptylamino]methylene}benzene-sulfonamide | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-11-22 | — | — | US | disclosed |
| EP-2091939-B1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-03-16 | — | — | EP | disclosed |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2008-09-04 | — | — | US | disclosed |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2008-09-04 | — | — | US | disclosed |
| WO-2008084057-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008074816-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-06-26 | — | — | WO | disclosed |
| US-7230024-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7145012-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| US-20060205720-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| EP-1622909-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004094429-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205720-A1 | Cannabinoid receptor ligands and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885ADRB2 162/4885 |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885ADRB2 162/4885 |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885ADRB2 163/4885 |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | CNR1, OPRL1, CNR2 | CNR1 1/4885CNR2 3/4885ADRB2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.